<?xml version='1.0' encoding='utf-8'?>
<document id="26758853"><sentence text="Identification of Human Sulfotransferases Involved in Lorcaserin N-Sulfamate Formation."><entity charOffset="54-76" id="DDI-PubMed.26758853.s1.e0" text="Lorcaserin N-Sulfamate" /></sentence><sentence text="Lorcaserin [(R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine] hydrochloride hemihydrate, a selective serotonin 5-hydroxytryptamine (5-HT) 5-HT(2C) receptor agonist, is approved by the U"><entity charOffset="0-96" id="DDI-PubMed.26758853.s2.e0" text="Lorcaserin [(R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine] hydrochloride hemihydrate" /><entity charOffset="110-139" id="DDI-PubMed.26758853.s2.e1" text="serotonin 5-hydroxytryptamine" /><entity charOffset="141-145" id="DDI-PubMed.26758853.s2.e2" text="5-HT" /><entity charOffset="147-150" id="DDI-PubMed.26758853.s2.e3" text="5-HT" /><pair ddi="false" e1="DDI-PubMed.26758853.s2.e0" e2="DDI-PubMed.26758853.s2.e0" /><pair ddi="false" e1="DDI-PubMed.26758853.s2.e0" e2="DDI-PubMed.26758853.s2.e1" /><pair ddi="false" e1="DDI-PubMed.26758853.s2.e0" e2="DDI-PubMed.26758853.s2.e2" /><pair ddi="false" e1="DDI-PubMed.26758853.s2.e0" e2="DDI-PubMed.26758853.s2.e3" /><pair ddi="false" e1="DDI-PubMed.26758853.s2.e1" e2="DDI-PubMed.26758853.s2.e1" /><pair ddi="false" e1="DDI-PubMed.26758853.s2.e1" e2="DDI-PubMed.26758853.s2.e2" /><pair ddi="false" e1="DDI-PubMed.26758853.s2.e1" e2="DDI-PubMed.26758853.s2.e3" /><pair ddi="false" e1="DDI-PubMed.26758853.s2.e2" e2="DDI-PubMed.26758853.s2.e2" /><pair ddi="false" e1="DDI-PubMed.26758853.s2.e2" e2="DDI-PubMed.26758853.s2.e3" /></sentence><sentence text="S" /><sentence text=" Food and Drug Administration for chronic weight management" /><sentence text=" Lorcaserin is primarily cleared by metabolism, which involves multiple enzyme systems with various metabolic pathways in humans"><entity charOffset="1-11" id="DDI-PubMed.26758853.s5.e0" text="Lorcaserin" /></sentence><sentence text=" The major circulating metabolite is lorcaserin N-sulfamate"><entity charOffset="37-59" id="DDI-PubMed.26758853.s6.e0" text="lorcaserin N-sulfamate" /></sentence><sentence text=" Both human liver and renal cytosols catalyze the formation of lorcaserin N-sulfamate, where the liver cytosol showed a higher catalytic efficiency than renal cytosol"><entity charOffset="63-85" id="DDI-PubMed.26758853.s7.e0" text="lorcaserin N-sulfamate" /></sentence><sentence text=" Human sulfotransferases (SULTs) SULT1A1, SULT1A2, SULT1E1, and SULT2A1 are involved in the formation of lorcaserin N-sulfamate"><entity charOffset="105-127" id="DDI-PubMed.26758853.s8.e0" text="lorcaserin N-sulfamate" /></sentence><sentence text=" The catalytic efficiency of these SULTs for lorcaserin N-sulfamate formation is widely variable, and among the SULT isoforms SULT1A1 was the most efficient"><entity charOffset="45-67" id="DDI-PubMed.26758853.s9.e0" text="lorcaserin N-sulfamate" /></sentence><sentence text=" The order of intrinsic clearance for lorcaserin N-sulfamate is SULT1A1 &gt; SULT2A1 &gt; SULT1A2 &gt; SULT1E1"><entity charOffset="38-60" id="DDI-PubMed.26758853.s10.e0" text="lorcaserin N-sulfamate" /></sentence><sentence text=" Inhibitory effects of lorcaserin N-sulfamate on major human cytochrome P450 (P450) enzymes were not observed or minimal"><entity charOffset="23-45" id="DDI-PubMed.26758853.s11.e0" text="lorcaserin N-sulfamate" /></sentence><sentence text=" Lorcaserin N-sulfamate binds to human plasma protein with high affinity (i"><entity charOffset="1-23" id="DDI-PubMed.26758853.s12.e0" text="Lorcaserin N-sulfamate" /></sentence><sentence text="e" /><sentence text=", &gt;99%)" /><sentence text=" Thus, despite being the major circulating metabolite, the level of free lorcaserin N-sulfamate would be minimal at a lorcaserin therapeutic dose and unlikely be sufficient to cause drug-drug interactions"><entity charOffset="73-95" id="DDI-PubMed.26758853.s15.e0" text="lorcaserin N-sulfamate" /><entity charOffset="118-128" id="DDI-PubMed.26758853.s15.e1" text="lorcaserin" /><pair ddi="false" e1="DDI-PubMed.26758853.s15.e0" e2="DDI-PubMed.26758853.s15.e0" /><pair ddi="false" e1="DDI-PubMed.26758853.s15.e0" e2="DDI-PubMed.26758853.s15.e1" /></sentence><sentence text=" Considering its formation kinetic parameters, high plasma protein binding affinity, minimal P450 inhibition or induction potential, and stability, the potential for metabolic drug-drug interaction or toxicological effects of lorcaserin N-sulfamate is remote in a normal patient population"><entity charOffset="226-248" id="DDI-PubMed.26758853.s16.e0" text="lorcaserin N-sulfamate" /></sentence><sentence text="" /></document>